Sinovac Biotech (FRA:SVQ) Total Long-Term Assets: €1,314.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SVQ Sinovac Biotech Ltd FRA:SVQ
12 GF Score
Price €5.58
! 9 Warning Signs
View Full Analysis

What is Sinovac Biotech Total Long-Term Assets?

Sinovac Biotech FRA:SVQ 12 Total Long-Term Assets is €1,314.5 Mil as of Jun. 2026. GuruFocus rates FRA:SVQ with a GF Score™ of 12/100. The stock has 9 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Sinovac Biotech's Total Long-Term Assets for the quarter that ended in Jun. 2026 was €1,314.5 Mil.

Sinovac Biotech Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Sinovac Biotech's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech Total Long-Term Assets Chart

Sinovac Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,622.26 1,876.83 1,675.74 1,616.59 1,261.55

Sinovac Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,624.50 1,616.59 1,396.11 1,261.55 1,314.48
FRA:SVQ
12GF Score
Sinovac Biotech Ltd FRA:SVQ
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinovac Biotech Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €1,314.5 Mil mean?
Sinovac Biotech (FRA:SVQ) has a Total Long-Term Assets of €1,314.5 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Sinovac Biotech and its competitors.
Is Sinovac Biotech's Total Long-Term Assets too high?
Sinovac Biotech's current Total Long-Term Assets is €1,314.5 Mil. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's Total Long-Term Assets compare to INBX and HLVX?
Sinovac Biotech's Total Long-Term Assets of €1,314.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Sinovac Biotech and its competitors. Sinovac Biotech's current Total Long-Term Assets is €1,314.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (FRA:SVQ) has a current Total Long-Term Assets of €1,314.5 Mil. The current Total Long-Term Assets is €1,314.5 Mil. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Sinovac Biotech (FRA:SVQ), the current Total Long-Term Assets is €1,314.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinovac Biotech Business Description

Address No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score

Get the complete analysis for FRA:SVQ

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.58
Price